Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC

PHASE2RecruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

March 24, 2020

Primary Completion Date

March 24, 2025

Study Completion Date

March 24, 2026

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Crizotinib

Crizotinib 250mg po bid. Savolitinib 300mg po, qd.

DRUG

Pemetrexed

Pemetrexed, 500mg/m2, ivgtt erery 21day.

Trial Locations (1)

RECRUITING

Yongchang Zhang, Changsha

All Listed Sponsors

lead

Hunan Province Tumor Hospital

OTHER